Stockscreener 앱 받기
0.7363
9.49%
-0.0777
전일 마감가:
$0.8139
열려 있는:
$0.83
하루 거래량:
3.83M
Relative Volume:
1.01
시가총액:
$114.83M
수익:
$126.33M
순이익/손실:
$-82.68M
주가수익비율:
-0.5938
EPS:
-1.24
순현금흐름:
$-79.98M
1주 성능:
+24.42%
1개월 성능:
-9.45%
6개월 성능:
-19.05%
1년 성능:
-29.50%
1일 변동 폭
$0.7282
$0.8795
1주일 범위
$0.5406
$0.8845
52주 변동 폭
$0.54
$2.05
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MCRB | 0.7367 | 114.83M | 126.33M | -82.68M | -79.98M | -1.24 |
| VRTX | 450.36 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.27 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.08 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.36 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.36 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 By Investing.com - Investing.com South Africa
Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 - Investing.com India
Seres Therapeutics Q3 2024 Earnings Preview - MSN
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Rising Disease Prevalence Driving Revenue, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve
Seres Therapeutics chief legal officer sells shares worth $474 - Investing.com
Seres Therapeutics executive sells shares worth $397 - Investing.com
Seres Therapeutics executive sells shares worth $397 By Investing.com - Investing.com UK
Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World
Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023) - Yahoo Finance
Canaccord Genuity Group Reiterates "Buy" Rating for Seres Therapeutics (NASDAQ:MCRB) - MarketBeat
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript - Insider Monkey
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... By GuruFocus - Investing.com Canada
Earnings call: Seres Therapeutics reports key Q3 2024 milestones - Investing.com
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... - Yahoo Finance
Seres Therapeutics Reports Q3 2024 Results and Strategic Progress - TipRanks
Seres reports Q3 EPS from continuing operations (33c), consensus (24c) - TipRanks
Seres Therapeutics expects cash to fund operations into Q4 of 2025 - TipRanks
Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success - TipRanks
Seres Therapeutics: Q3 Earnings Snapshot - New Haven Register
Seres Therapeutics reports Q3 EPS 58c, consensus (24c) - TipRanks
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Seres' SER-155 Shows 77% Infection Reduction; Nets $175M from Nestlé Deal | MCRB Stock News - StockTitan
Seres Therapeutics (MCRB) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 - The Manila Times
Seres Therapeutics Q3 2024 Earnings Call: MCRB Sets Key November Date | MCRB Stock News - StockTitan
Seres Therapeutics chief legal officer sells $2,939 in stock By Investing.com - Investing.com Australia
Seres Therapeutics exec von Moltke sells $2,991 in stock By Investing.com - Investing.com Canada
Seres Therapeutics executive sells shares worth $2,058 By Investing.com - Investing.com Canada
Seres Therapeutics executive sells shares worth $2,058 - Investing.com India
Seres Therapeutics executive sells stock for $2,749 By Investing.com - Investing.com Australia
Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock - Investing.com India
Seres Therapeutics chief legal officer sells $2,939 in stock - Investing.com India
Seres Therapeutics exec von Moltke sells $2,991 in stock - Investing.com
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 17% of holdings value - Simply Wall St
This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - MSN
Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $5.08 Consensus Price Target from Analysts - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Stock Rating Lowered by JPMorgan Chase & Co. - MarketBeat
Seres cut to underweight by JP Morgan on Vowst sale - MSN
Seres cut to underweight by JP Morgan on Vowst sale (NASDAQ:MCRB) - Seeking Alpha
Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Seres Therapeutics Inc (MCRB)’s stock price range in the last year - US Post News
Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below 50 Day Moving AverageHere's What Happened - MarketBeat
Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Strong at 0.81, Up 4.77 - The Dwinnex
The time has not yet come to remove your chips from the table: Seres Therapeutics Inc (MCRB) - SETE News
Introducing Our Rant Against Seres Therapeutics Inc - US Post News
Seres Therapeutics gains amid takeover speculation - MSN
Seres Therapeutics Inc [MCRB] is -44.91% lower this YTD. Is it still time to buy? - The DBT News
An analyst sees good growth prospects for Seres Therapeutics Inc (MCRB) - SETE News
Seres Therapeutics Inc (MCRB) Stock: A Year of Declines and Increases - The InvestChronicle
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):